# Aspirin for the Prevention of Ischemic Complications in Giant Cell Arteritis

Study · id `cardio:ct-nct07908082` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07908082](<https://clinicaltrials.gov/study/NCT07908082>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT07908082

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 120 participants.

## Technical summary

Registry record NCT07908082. Randomized; quadruple masking; primary purpose prevention. Start 2027-10 (anticipated); primary completion 2030-10 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose prevention
- Phase: Phase 3
- Enrolled: 120 participants (planned count; ClinicalTrials.gov record NCT07908082, source copy `cardio:ctgov-nct07908082-2026-10-30`, retrieved 2026-10-31)
- Planned start: 2027-10 (anticipated) (ClinicalTrials.gov record NCT07908082, source copy `cardio:ctgov-nct07908082-2026-10-30`, retrieved 2026-10-31)
- Primary completion: 2030-10 (anticipated) (ClinicalTrials.gov record NCT07908082, source copy `cardio:ctgov-nct07908082-2026-10-30`, retrieved 2026-10-31)
- Completion: 2030-10 (anticipated) (ClinicalTrials.gov record NCT07908082, source copy `cardio:ctgov-nct07908082-2026-10-30`, retrieved 2026-10-31)
- Countries: Canada (ClinicalTrials.gov record NCT07908082, source copy `cardio:ctgov-nct07908082-2026-10-30`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "NOT\_YET\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07908082-2026-10-30`, retrieved 2026-10-31)

## The registry's words

- Brief title: Aspirin for the Prevention of Ischemic Complications in Giant Cell Arteritis
- Acronym: ASPIRE-GCA
- Condition: Giant Cell Arteritis (GCA)
- Condition: Acute Coronary Syndrome (ACS)
- Condition: Ishemic and Thrombotic Complications
- Intervention (Drug): Acetyl Salicylic Acid (ASA)
- Intervention (Drug): Placebo
- Lead sponsor: Centre Integre Universitaire de Sante et Services Sociaux du Nord de l'ile de Montreal
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Acute coronary syndrome (`cardio:acute-coronary-syndrome`)
- Registry lists this organization as the lead sponsor: Centre Integre Universitaire de Sante et Services Sociaux du Nord de l'ile de Montreal (`cardio:org-centre-integre-universitaire-de-sante-et-services-sociaux-f20430`)

## Provenance

Content hash: 6506f52ae5e93218e4db98ff8b5c233dae5d10fb47ecc6c0bd9761fd45ab3ebd
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
